213 related articles for article (PubMed ID: 34814865)
1. Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis.
Jessen H; Hoyer N; Prior TS; Frederiksen P; Rønnow SR; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB; Shaker SB
BMC Pulm Med; 2021 Nov; 21(1):382. PubMed ID: 34814865
[TBL] [Abstract][Full Text] [Related]
2. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis.
Jessen H; Hoyer N; Prior TS; Frederiksen P; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB; Shaker SB
Respir Res; 2021 Jul; 22(1):205. PubMed ID: 34261485
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.
Jenkins RG; Simpson JK; Saini G; Bentley JH; Russell AM; Braybrooke R; Molyneaux PL; McKeever TM; Wells AU; Flynn A; Hubbard RB; Leeming DJ; Marshall RP; Karsdal MA; Lukey PT; Maher TM
Lancet Respir Med; 2015 Jun; 3(6):462-72. PubMed ID: 25770676
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort.
Organ LA; Duggan AR; Oballa E; Taggart SC; Simpson JK; Kang'ombe AR; Braybrooke R; Molyneaux PL; North B; Karkera Y; Leeming DJ; Karsdal MA; Nanthakumar CB; Fahy WA; Marshall RP; Jenkins RG; Maher TM
Respir Res; 2019 Jul; 20(1):148. PubMed ID: 31299951
[TBL] [Abstract][Full Text] [Related]
5. High turnover of types III and VI collagen in progressive idiopathic pulmonary fibrosis.
Hoyer N; Jessen H; Prior TS; Sand JMB; Leeming DJ; Karsdal MA; Åttingsberg EKA; Vangsgaard GKM; Bendstrup E; Shaker SB
Respirology; 2021 Jun; 26(6):582-589. PubMed ID: 33834579
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD.
Bihlet AR; Karsdal MA; Sand JM; Leeming DJ; Roberts M; White W; Bowler R
Respir Res; 2017 Jan; 18(1):22. PubMed ID: 28103932
[TBL] [Abstract][Full Text] [Related]
7. Collagen Type III and VI Turnover in Response to Long-Term Immobilization.
Sun S; Henriksen K; Karsdal MA; Byrjalsen I; Rittweger J; Armbrecht G; Belavy DL; Felsenberg D; Nedergaard AF
PLoS One; 2015; 10(12):e0144525. PubMed ID: 26641456
[TBL] [Abstract][Full Text] [Related]
8. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
9. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
[TBL] [Abstract][Full Text] [Related]
10. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis.
Hesse C; Beneke V; Konzok S; Diefenbach C; Bülow Sand JM; Rønnow SR; Karsdal MA; Jonigk D; Sewald K; Braun A; Leeming DJ; Wollin L
Respir Res; 2022 Aug; 23(1):201. PubMed ID: 35927669
[TBL] [Abstract][Full Text] [Related]
12. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
Ikeda K; Chiba H; Nishikiori H; Azuma A; Kondoh Y; Ogura T; Taguchi Y; Ebina M; Sakaguchi H; Miyazawa S; Suga M; Sugiyama Y; Nukiwa T; Kudoh S; Takahashi H;
Respir Res; 2020 Nov; 21(1):316. PubMed ID: 33256760
[TBL] [Abstract][Full Text] [Related]
13. LPA
Decato BE; Leeming DJ; Sand JMB; Fischer A; Du S; Palmer SM; Karsdal M; Luo Y; Minnich A
Respir Res; 2022 Mar; 23(1):61. PubMed ID: 35303880
[TBL] [Abstract][Full Text] [Related]
14. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.
Maher TM; Oballa E; Simpson JK; Porte J; Habgood A; Fahy WA; Flynn A; Molyneaux PL; Braybrooke R; Divyateja H; Parfrey H; Rassl D; Russell AM; Saini G; Renzoni EA; Duggan AM; Hubbard R; Wells AU; Lukey PT; Marshall RP; Jenkins RG
Lancet Respir Med; 2017 Dec; 5(12):946-955. PubMed ID: 29150411
[TBL] [Abstract][Full Text] [Related]
15. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
Adegunsoye A; Alqalyoobi S; Linderholm A; Bowman WS; Lee CT; Pugashetti JV; Sarma N; Ma SF; Haczku A; Sperling A; Strek ME; Noth I; Oldham JM
Chest; 2020 Oct; 158(4):1526-1534. PubMed ID: 32450241
[TBL] [Abstract][Full Text] [Related]
16. Integrated plasma proteomics and lung transcriptomics reveal novel biomarkers in idiopathic pulmonary fibrosis.
Sivakumar P; Ammar R; Thompson JR; Luo Y; Streltsov D; Porteous M; McCoubrey C; Cantu E; Beers MF; Jarai G; Christie JD
Respir Res; 2021 Oct; 22(1):273. PubMed ID: 34689792
[TBL] [Abstract][Full Text] [Related]
17. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab.
Nissen NI; Kehlet S; Boisen MK; Liljefors M; Jensen C; Johansen AZ; Johansen JS; Erler JT; Karsdal M; Mortensen JH; Høye A; Willumsen N
Sci Rep; 2021 Jan; 11(1):865. PubMed ID: 33441622
[TBL] [Abstract][Full Text] [Related]
19. Characterization of serological neo-epitope biomarkers reflecting collagen remodeling in clinically stable chronic obstructive pulmonary disease.
Sand JM; Martinez G; Midjord AK; Karsdal MA; Leeming DJ; Lange P
Clin Biochem; 2016 Oct; 49(15):1144-1151. PubMed ID: 27614218
[TBL] [Abstract][Full Text] [Related]
20. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.
Huang TH; Kuo CW; Chen CW; Tseng YL; Wu CL; Lin SH
BMC Pulm Med; 2021 May; 21(1):165. PubMed ID: 33992083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
